Ambit Biosciences Inc. logo
Ambit Biosciences Inc. logo

Ambit Biosciences Inc.

ambitbio.com
ambitbio.com · 501-1000 employees
501-1000 employees
Biologics & Biosimilars
Biotechnology
Health Care
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials

Overview

Ambit Biosciences Corporation. We are a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases.

News

Blog 5 months ago
A quantitative analysis of kinase inhibitor selectivity Read more
Report
Blog 5 months ago
Publications Read more
Report
Blog 5 months ago
Quizartinib (AC220) in Patients With FLT3-ITD(+) Relapsed or Refractory Acute Myeloid Leukemia: Final Results of a Randomized Phase 2 Study
Background FLT3-ITD in AML is associated with early relapse and poor survival after treatment with standard chemotherapy Quizartinib is an orally active FLT3-ITD inhibitor A previous Phase 2 study included subjects with FLT3-ITD(+) AML, relapsed/refractor
Read more
Report
Blog 5 months ago
A small molecule-kinase interaction map for clinical kinase inhibitors
Kinase inhibitors show great promise as a new class of therapeutics. Here we describe an efficient way to determine kinase inhibitor specificity by measuring binding of small molecules to the ATP site of kinases. We have profiled 20 kinase inhibitors, inc
Read more
Report
Blog 2 years ago
Skilled. Resourceful. Validated. Read more
Report
Blog 2 years ago
Clinical Trials Read more
Report
Blog 2 years ago
Strategic Partnerships Read more
Report
Blog 2 years ago
Scientific Publications & Presentations Read more
Report
Blog 2 years ago
CEP-32496 Development Read more
Report
Blog 2 years ago
About quizartinib Read more
Report
Show more news